[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"European Foundation for Study of Chronic Liver Failure\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":97},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100409625","liver-transplantation-in-patients-with-cirrhosis-and-severe-acute-on-chronic-liver-failure-indications-and-outcomes-100409625",false,"NCT04613921","Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs","Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure (ACLF): iNdications and outComEs","CHANCE","Inclusion Criteria:\n\n* 1\\. Male or female subject ≥18 years of age.\n\n  2\\. Subjects with diagnosis of liver cirrhosis (based on clinical, laboratory, endoscopic, and ultrasonographic features or on histology).\n\n  3\\. Subjects who have been hospitalized for acute decompensation of liver cirrhosis and referred to the transplant team:\n* Group 1: patients listed for liver transplantation with ACLF-2 or 3 at the time of listing or developing ACLF 2-3 while on the waiting list.\n* Group 2: patients listed for liver transplantation with decompensated cirrhosis without ACLF-2 or 3 and poor liver function (MELD\\>20) at the time of listing.\n* Group 3: patients having ACLF-2 or 3, are assessed for inclusion in the waiting list, but are finally not listed for liver transplantation.\n\n  4\\. Patients (or trusted person, family member or close relation if the patient is unable to express consent) who have been informed and signed their informed consent Inclusion criteria\n\nExclusion Criteria:\n\n\\-","ALL","18 Years","80 Years",{"count":21,"type":22},3000,"ESTIMATED","OBSERVATIONAL","Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of deceased donors obliges to maximize LT success. Alternative strategies, as living-donor LT, should be explored. LDLT has impressive results in Eastern centers, but it is restrained in Western countries, due to potential life-threatening complications in the donor.",[26,27,28,29],"Liver Diseases","Liver Cirrhosis","Acute-On-Chronic Liver Failure","Liver Transplant; Complications","RECRUITING","2025-10-15",{"date":33,"type":34},"2025-10-20","ACTUAL",{"date":36,"type":34},"2021-07-08",{"date":38,"type":22},"2026-12-31",{"name":40,"class":41},"European Foundation for Study of Chronic Liver Failure","OTHER",106,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100581803","validation-of-new-prognostic-biomarkers-in-patients-with-decompensated-cirrhosis-100581803","NCT06855056","Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis","Validation of New Prognostic biomarkerRs in Patients With cirrhOsis diScharged After a hosPitalization Due to acutE deCompensation or acuTe-on-chronic Liver Failure","PROSPECT","Inclusion Criteria:\n\n1. Age between 18 and 80 years.\n2. Patients with decompensated cirrhosis admitted to hospital due to AD according to the EASL-CLIF criteria (rapid onset of ascites, hepatic encephalopathy, portal hypertensive- related gastrointestinal bleeding, bacterial infection, or any combination of these), including those who presented ACLF during hospitalization.\n3. Recovery from AD and expected to be discharged within the next 48 hours.\n\nExclusion Criteria:\n\n1. Admission for planned diagnostic or therapeutic procedures\n2. Active malignancy (except for hepatocellular carcinoma within the Milan criteria or nonmelanocytic skin cancer)\n3. Antiviral treatment for hepatitis C, B and delta initiated in the last 6 months or planned to be initiated in the following 6 months.\n4. HIV positive (except undergoing treatment and who do not exhibit clinical manifestations of AIDS).\n5. Ongoing alcohol use disorder with an expected low adherence to prescriptions as judged by physician\n6. Previous liver or other organ transplantation\n7. Patients with TIPS or other surgical porto-caval shunts\n8. Chronic organic renal failure stage IV and V or estimated Glomerular Filtration Rate \\\u003C20 ml\u002Fmin according to the MDRD equations\n9. Chronic heart failure NYHA class III or IV\n10. Pulmonary disease GOLD III or IV\n11. Patients with a history of significant extrahepatic disease with life expectancy \\\u003C6 months\n12. Severe psychiatric disorders\n13. Pregnancy and breast-feeding\n14. Expected low adherence to study protocol as judged by physician\n15. Patients who cannot provide written informed consent or refuse to participate",{"count":52,"type":22},189,"The study aims to test the effectiveness of new biomarkers (measurable molecules in our body) in predicting the health outcome of patients with liver cirrhosis discharged from the hospital after a serious complication of the disease",[27,55],"Decompensated Cirrhosis of Liver",[57,58,26,27,59],"Decompensated Liver Cirrhosis","Acute on Chronic Liver Failure (ACLF)","Biomarkers","2025-08-05",{"date":62,"type":34},"2025-08-06",{"date":64,"type":34},"2025-03-01",{"date":66,"type":22},"2026-09-30",{"name":40,"class":41},9,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":68},"100508033","phase-2-a-novel-combinatorial-therapy-with-albumin-and-enoxaparin-in-patients-with-decompensated-cirrhosis-at-high-risk-of-poor-outcome-combat-trial-100508033","NCT05895136","A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).","COMBAT","Inclusion Criteria:\n\n1. Age between 18 and 80 years.\n2. Patients with decompensated cirrhosis admitted to hospital due to AD according to the EASL-CLIF criteria (rapid onset of ascites, hepatic encephalopathy, portal hypertensive-related gastrointestinal bleeding, bacterial infection, or any combination of these).\n3. CLIF-C AD score ≥ 45 at admission or at any time during hospital stay.\n4. Recovery from AD and expected to be discharged within the next 72 hours.\n\nExclusion Criteria:\n\n1. Diagnosis of acute-on-chronic liver failure (ACLF) grade 3 or higher according to the EASL-CLIF criteria at admission or at any time during the index hospitalization\n2. Admission for planned diagnostic or therapeutic procedures\n3. Recent acute bleeding (unless the cause has been effectively treated and there is no evidence of ongoing bleeding for at least 5 days)\n4. Chronic bleeding requiring periodic blood transfusions\n5. Presence of an ongoing acute complication of the disease (i.e. hepatic encephalopathy \\[grade III or IV\\])\n6. Conditions with a high risk of haemorrhage, including haemorrhagic diathesis not related to liver disease\n7. Patients with INR \\> 3.0\n8. Severe thrombocytopenia (\\\u003C30x10 9 \u002FL)\n9. Ongoing chronic anticoagulation therapy or indication for starting anticoagulation due to hepatic and non-hepatic conditions\n10. Ongoing anti-platelets therapy.\n11. Active malignancy (except for hepatocellular carcinoma within the Milan criteria or non-melanocytic skin cancer)\n12. Antiviral treatment for hepatitis C, B and delta initiated in the last 6 months or planned to be initiated in the following 6 months\n13. Ongoing alcohol use disorder with an expected low adherence to protocol as judged by physician\n14. Previous liver transplantation\n15. Patients with TIPS or other surgical porto-caval shunts\n16. Chronic organic renal failure stage IV and V or estimated Glomerular Filtration Rate \\\u003C30 ml\u002Fmin according to the MDRD equations\n17. Chronic heart failure NYHA class III or IV\n18. Pulmonary disease GOLD III or IV\n19. Patients with extrahepatic diseases with life expectancy \\\u003C6 months\n20. Severe psychiatric disorders\n21. Hypersensitivity to albumin preparations or to any of the excipients.\n22. Hypersensitivity to enoxaparin sodium, heparin or its derivatives, including other low molecular weight heparins (LMWH) or to any of the excipients\n23. History of immune mediated heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies\n24. Pregnancy and breast-feeding\n25. Expected low adherence to study protocol as judged by physician\n26. Patients who can't provide written informed consent or refusal to participate\n27. Participation in other concurrent clinical trials and within the prior 3 months from informed consent signature.",{"count":77,"type":22},90,"INTERVENTIONAL",[80],"PHASE2","The goal of this clinical trial is to determine primarily whether a combinatorial therapy based on the administration of human albumin and enoxaparin is safe and effective in patients with decompensated cirrhosis discharged from the hospital. The main questions it aims to answer are:\n\n* Is this combinatorial therapy safe and tolerable?\n* Is this combinatorial therapy effective?\n* does this combinatorial therapy cost more or less than standard medical therapy? Participants will attend to study visits in which several test will be performed to asses disease evolution while they are taking study medication.\n\nResearchers will compare experimental group treated with combinatorial therapy plus standard treatment with control group treated with standard treatment to see if there are differences in the responses to the questions raised above.",[27,55,58],[84,58,85,86,87,88],"decompensated cirrhosis","Liver diseases","liver cirrhosis","Human Albumin","Enoxaparin","2025-03-14",{"date":91,"type":34},"2025-03-19",{"date":93,"type":34},"2024-07-01",{"date":95,"type":22},"2025-09",{"name":40,"class":41},""]